9 Results for "

Nicotinamide-13C6

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Nicotinamide-13C6" in MCE Product Catalog:

  • Targets Recommended:
1
1 Cited Publications
Cat. No.: HY-P1103
CAS No.: 1030384-98-5
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
Cat. No.: HY-P4070
CAS No.: 1188379-43-2
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
Cat. No.: HY-B0150S2
CAS No.: 2749910-55-0
Synonyms: Niacinamide-13C6; Nicotinic acid amide-13C6
Nicotinamide- 13C6 is the 13C-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.
Cat. No.: HY-P1103A
Target:  

CXCR

Research Areas:  

Cancer

CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
Cat. No.: HY-P11293
CAS No.: 1309855-53-5
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
Cat. No.: HY-P4757
CAS No.: 108081-77-2
Target:  

Parasite

Research Areas:  

Others

N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
Cat. No.: HY-P1321
CAS No.: 158859-98-4
Synonyms: 1229U91; GW1229
Research Areas:  

Neurological Disease

GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
Cat. No.: HY-P1321A
Synonyms: 1229U91 TFA; GW1229 TFA
Research Areas:  

Neurological Disease

GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
Cat. No.: HY-P11480
CAS No.: 3105660-96-3
Target:  

Trk Receptor

Research Areas:  

Neurological Disease

TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC50: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .